<DOC>
	<DOCNO>NCT00649636</DOCNO>
	<brief_summary>The objective study investigate bioequivalence Mylan 's fluoxetine hydrochloride 40 mg capsule Dista 's Prozac 40 mg pulvules follow single , oral 40 mg ( 1 x 40 mg ) dose administration fasting condition .</brief_summary>
	<brief_title>Fasting Study Fluoxetine Capsules 40 mg Prozac Pulvules 40 mg</brief_title>
	<detailed_description />
	<mesh_term>Fluoxetine</mesh_term>
	<criteria>1 . Age : 18 year old . 2 . Sex : Male and/or nonpregnant , nonlactating female . . Women childbearing potential must negative serum beta human chorionic gonadotropin ( bHCG ) pregnancy test perform within 21 day prior start study even prior dose administration . If dose schedule weekend , HCG pregnancy test give within 48 hour prior dose study period . An additional serum ( bHCG ) pregnancy test perform upon completion study . b . Women childbearing potential must practice abstinence use acceptable form contraception throughout duration study . No hormonal contraceptive hormone replacement therapy permit study . Acceptable form contraception include follow : 1 ) intrauterine device place least 3 month prior start study remain place study period , 2 ) barrier method contain use conjunction spermicidal agent , 3 ) surgical sterility ( tubal ligation , oophorectomy hysterectomy ) postmenopausal accompany document postmenopausal course least one year . c. Women consider childbearing potential one follow report documented medical history : 1 ) postmenopausal absence menses least one 2 ) bilateral oophorectomy without hysterectomy 3 ) total hysterectomy d. During course study , study screen study exit , men woman childbearing potential must use spermicidecontaining barrier method contraception addition current contraceptive device . This requirement document informed consent form . 3 . Weight : At least 60 kg ( 132 lb ) men 48 kg ( 106 lb ) woman subject Body Mass Index ( BMI ) less equal 30 great equal 19 . ( See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS ) . 4 . All subject judge normal healthy prestudy medical evaluation ( physical examination , laboratory evaluation , Hepatitis B Hepatitis C test , HIV test , 12lead ECG , urine drug screen include amphetamine , barbiturate , benzodiazepine , cannabinoid , cocaine , opiates , phencyclidine , methadone ) perform within 21 day initial dose study medication . 1 . Institutionalized subject use . 2 . Social Habits : . Use tobacco product within one year prior dose . b. Ingestion alcoholic , caffeine xanthinecontaining food beverage within 48 hour prior initial dose study medication . c. Ingestion vitamin herbal product within 7 day prior initial dose study medication . d. Any recent , significant change dietary exercise habit . e. A positive test drug include urine drug screen . f. History drug and/or alcohol abuse . 3 . Medications : . Use prescription overthecounter ( OTC ) medication within 14 day prior initial dose study medication , especially monoamine oxidase inhibitor ( MAOI ) . b . Use hormonal contraceptive hormone replacement therapy within 3 month prior study medication dosing . c. Use medication know alter hepatic enzyme activity within 35 day prior initial dose study medication . 4 . Diseases : . History significant cardiovascular , hepatic , renal , pulmonary , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic disease . b . Acute illness time either prestudy medical evaluation dosing . c. A positive HIV , Hepatitis B , Hepatitis C test . d. History seizure psychiatric disorder . 5 . Abnormal clinically significant laboratory test result : a. Clinically significant deviation Guide Clinically Relevant Abnormalities ( See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS ) . b. Abnormal clinically relevant ECG tracing . 6 . Donation loss significant volume blood plasma ( &gt; 450 mL ) within 28 day prior initial dose study medication . 7 . Subjects receive investigational drug within 30 day prior initial dose study medication . 8 . Allergy hypersensitivity fluoxetine , inactive ingredient , related product . 9 . History difficulty swallow , gastrointestinal disease could affect drug absorption . 10 . Consumption grapefruit grapefruit containing product within 7 day drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>